



OPEN ACCESS

EDITED AND REVIEWED BY
Zhongheng Zhang,
Sir Run Run Shaw Hospital, China

*CORRESPONDENCE

Dawid L. Staudacher
✉ dawid.staudacher@uniklinik-freiburg.de

RECEIVED 22 April 2024
ACCEPTED 20 May 2024
PUBLISHED 29 May 2024

CITATION

Rottmann FA, Noe C, Bemtgen X, Maier S,
Supady A, Wengenmayer T and Staudacher DL
(2024) Corrigendum: Survival outcomes and
mobilization during venovenous
extracorporeal membrane oxygenation: a
retrospective cohort study.
Front. Med. 11:1421367.
doi: 10.3389/fmed.2024.1421367

COPYRIGHT

© 2024 Rottmann, Noe, Bemtgen, Maier,
Supady, Wengenmayer and Staudacher. This is
an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Corrigendum: Survival outcomes and mobilization during venovenous extracorporeal membrane oxygenation: a retrospective cohort study

Felix A. Rottmann¹, Christian Noe², Xavier Bemtgen³,
Sven Maier⁴, Alexander Supady², Tobias Wengenmayer² and
Dawid L. Staudacher^{2*}

¹Department of Medicine IV—Nephrology and Primary Care, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany, ²Interdisciplinary Medical Intensive Care, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany, ³Department of Cardiology and Angiology I, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany, ⁴Department of Cardiovascular Surgery, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany

KEYWORDS

extracorporeal membrane oxygenation, muscle weakness, intensive care unit-acquired weakness, mobilization, acute respiratory distress syndrome, intensive & critical care, early ambulation, rehabilitation

A corrigendum on

[Survival outcomes and mobilization during venovenous extracorporeal membrane oxygenation: a retrospective cohort study](#)

by Rottmann, F. A., Noe, C., Bemtgen, X., Maier, S., Supady, A., Wengenmayer, T., and Staudacher, D. L. (2023). *Front. Med.* 10:1271540. doi: 10.3389/fmed.2023.1271540

In the published article, there was an error in [Tables 1, 2](#) as published. This error pertains to the continuous data presented in the primary manuscript. The median values and interquartile ranges were incorrect. It is crucial to note that the primary endpoint (mortality), figures, and all but one provided *p*-values ([Table 1](#)—Hypertension: $p = 0.4740$ was previously displayed and is incorrect. The correct *p*-value is 0.3092) remain unaffected, as they either do not involve continuous data or were calculated independently. The corrected [Tables 1, 2](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 1 Patients characteristics and endpoints by ICU mobility scale under V-V ECMO.

Baseline characteristics	Total (n = 343)	ICU mobility scale <2 (n = 281)	ICU mobility scale ≥2 (n = 62)	p-value
Percentage of patients	100	82	18	
Age	55 (45–64)	55 (45–64)	57 (42–63)	0.9014 ^a
Female gender	108 (31.5%)	90 (32%)	18 (29%)	0.7628 ^b
BMI	25.1 (23.6–30.2)	24.8 (23.5–30.2)	26.8 (23.8–30.6)	0.2358 ^a
Preexisting conditions				
Hypercholesterolemia	41 (12%)	34 (12.1%)	7 (11.3%)	0.9999 ^b
Nicotine use disorder	109 (31.8%)	89 (31.7%)	20 (32.3%)	0.9999 ^b
Coronary heart disease	37 (10.8%)	29 (10.3%)	8 (12.9%)	0.5058 ^b
Hypertension	124 (36.2%)	98 (34.9%)	26 (41.9%)	0.3092 ^b
Liver cirrhosis or chronic hepatitis	21 (6.1%)	20 (7.1%)	1 (1.6%)	0.1425 ^b
Chronic kidney disease	23 (6.7%)	20 (7.1%)	3 (4.8%)	0.7788 ^b
Diabetes mellitus	49 (14.3%)	40 (14.2%)	9 (14.5%)	0.9999 ^b
Oncological disorders	59 (17.2%)	52 (18.5%)	7 (11.3%)	0.1972 ^b
Immunodeficiency	93 (27.1%)	83 (29.5%)	10 (16.1%)	0.0394^b
Chronic lung disease	97 (28.3%)	79 (28.1%)	18 (29%)	0.8772 ^b
CPR within 48 h before EMCO	32 (9.3%)	30 (10.7%)	2 (3.2%)	0.0890^b
Respiratory situation before ECMO				
Horowitz index	70 (58–93)	71 (59–96)	64 (51–79)	0.0038^a
pO ₂ -arterial (mmHg)	65 (58–75)	66 (58–76)	62 (47–73)	0.0173^a
FiO ₂	1.0 (0.8–1.0)	1 (0.8–1)	1 (0.9–1)	0.1662 ^a
pCO ₂ -arterial (mmHg)	56 (46–73)	57 (46–73)	50 (43–72)	0.2392 ^a
pH-arterial	7.3 (7.2–7.3)	7.2 (7.2–7.3)	7.3 (7.2–7.4)	0.0002^a
Peak inspiratory pressure ≥42 cm H ₂ O	33 (9.6%)	30 (10.7%)	3 (4.8%)	0.2325 ^b
ICU stay				
Duration of ICU stay from ECMO d1 (d)	13.7 (8.7–26.8)	12.9 (7.3–21.5)	25.7 (13.8–53.4)	0.0001^a
ECMO runtime (h)	190 (114–361)	173 (100–288)	577 (243–1009)	0.0001^a
Mechanical ventilation (d)	11.8 (6.7–23.8)	10.9 (6.4–19.5)	25.4 (10.1–50.0)	0.0001^a
Endpoint				
30-day survival	179 (52.2%)	135 (48.0%)	44 (71.0%)	0.0012^b
ICU survival	160 (46.6%)	127 (45.2%)	33 (53.2%)	0.2636 ^b
Hospital survival	159 (46.4%)	126 (44.8%)	33 (53.2%)	0.2612 ^b
ECMO weaning	197 (57.4%)	159 (56.6%)	38 (61.3%)	0.5709 ^b
Vent. Weaning	169 (49.3%)	131 (46.6%)	38 (61.3%)	0.0489^b

Data given in median (interquartile range) or in number of patients (percentage of group). p-values are calculated between groups using either ^aMann–Whitney U-test or ^bFishers Exact test. BMI, body-mass-index; CPR, cardiopulmonary resuscitation; ECMO, extracorporeal membrane oxygenation; Vent., ventilation. Bold values indicate a p-value < 0.05.

TABLE 2 Patients characteristics and endpoints by best mobilization under V-V ECMO.

Baseline characteristics	Total (n = 343)	None (n = 179)	In bed (n = 102)	Edge of bed (n = 9)	Chair (n = 33)	Standing (n = 20)	p-value
Percentage of patients	100	52	30	3	10	6	
Age	55 (45–64)	54 (44–61)	59 (46–67)	50 (33–66)	56 (50–64)	58 (36–63)	0.2072 ^c
Female gender	108 (31.5%)	64 (35.8%)	26 (25.5%)	3 (33.3%)	11 (33.3%)	4 (20%)	0.3424 ^d
BMI	25.1 (23.6–30.2)	24.5 (23.5–30.1)	26.1 (23.9–30.6)	28.4 (24.8–39.6)	26.5 (23.9–31.8)	26.0 (21.4–29.4)	0.1174 ^c
Preexisting conditions							
Hypercholesterolemia	41 (12%)	20 (11.2%)	14 (13.7%)	2 (22.2%)	3 (9.1%)	2 (10%)	0.8018 ^d
Nicotine use disorder	109 (31.8%)	63 (35.2%)	26 (25.5%)	3 (33.3%)	11 (33.3%)	6 (30%)	0.5746 ^d
Coronary heart disease	37 (10.8%)	20 (11.2%)	9 (8.8%)	1 (11.1%)	5 (15.2%)	2 (10%)	0.8937 ^d
Hypertension	124 (36.2%)	61 (34.1%)	37 (36.3%)	3 (33.3%)	16 (48.5%)	7 (35%)	0.6355 ^d
Liver cirrhosis or chronic hepatitis	21 (6.1%)	18 (10.1%)	2 (2%)	0 (0%)	1 (3%)	0 (0%)	0.0352^d
Chronic kidney disease	23 (6.7%)	11 (6.1%)	9 (8.8%)	1 (11.1%)	2 (6.1%)	0 (0%)	0.6339 ^d
Diabetes mellitus	49 (14.3%)	27 (15.1%)	13 (12.7%)	0 (0%)	6 (18.2%)	3 (15%)	0.6975 ^d
Oncological disorders	59 (17.2%)	34 (19%)	18 (17.6%)	0 (0%)	4 (12.1%)	3 (15%)	0.5655 ^d
Immunodeficiency	93 (27.1%)	56 (31.3%)	27 (26.5%)	3 (33.3%)	4 (12.1%)	3 (15%)	0.1353 ^d
Chronic lung disease	97 (28.3%)	50 (27.9%)	29 (28.4%)	3 (33.3%)	9 (27.3%)	6 (30%)	0.9966 ^d
CPR within 48 h before EMCO	32 (9.3%)	23 (12.8%)	7 (6.9%)	0 (0%)	2 (6.1%)	0 (0%)	0.1494 ^d
Respiratory situation before ECMO							
Horowitz index	70 (58–93)	72 (60–107)	69 (58–87)	70 (61–102)	63 (49–77)	65 (46–96)	0.0091^c
pO ₂ -arterial (mmHg)	65 (58–75)	66 (58–78)	64 (56–71)	70 (59–80)	62 (44–71)	61 (45–73)	0.0164^c
FiO ₂	1.0 (0.8–1.0)	1 (0.8–1)	1 (0.8–1)	1 (0.9–1)	1 (1–1)	1 (0.8–1)	0.4644 ^c
pCO ₂ -arterial (mmHg)	56 (46–73)	56 (46–72)	59 (45–78)	51 (41–115)	54 (47–71)	48 (40–71)	0.6284 ^c
pH-arterial	7.3 (7.2–7.3)	7.2 (7.2–7.3)	7.3 (7.2–7.3)	7.3 (7.2–7.4)	7.4 (7.2–7.5)	7.3 (7.3–7.4)	0.0030^c
Peak inspiratory pressure ≥42 cm H ₂ O	33 (9.6%)	24 (13.4%)	6 (5.9%)	1 (11.1%)	0 (0%)	2 (10%)	0.0869 ^d
ICU stay							
Duration of ICU stay from ECMO d1 (d)	13.7 (8.7–26.8)	11.0 (5.9–18.0)	17.0 (9.5–29.7)	26.7 (14.4–57.3)	17.8 (10.8–42.8)	40.8 (21.7–72.6)	0.0001^c
ECMO runtime (d)	7.9 (4.7–15.0)	147 (80–239)	230 (147–413)	615 (169–852)	422 (220–778)	782 (407–1664)	0.0001^c
Mechanical ventilation (d)	11.8 (6.7–23.8)	9.5 (5.3–15.3)	14.8 (8.7–26.4)	26.7 (10.0–38.9)	19.1 (10.5–45.2)	38.1 (5.7–72.6)	0.0001^c
Endpoints							
30-day survival	179 (52.2%)	80 (44.7%)	55 (53.9%)	6 (66.7%)	22 (66.7%)	16 (80%)	0.0077^d
ICU survival	160 (46.6%)	78 (43.6%)	49 (48.0%)	4 (44.4%)	17 (51.5%)	12 (60%)	0.6406 ^d
Hospital survival	159 (46.4%)	78 (43.6%)	48 (47.1%)	4 (44.4%)	17 (51.5%)	12 (60%)	0.6553 ^d
ECMO weaning	197 (57.4%)	103 (57.5%)	56 (54.9%)	5 (55.6%)	19 (57.6%)	14 (70%)	0.8136 ^d
Vent. Weaning	169 (49.3%)	80 (44.7%)	51 (50.0%)	5 (55.6%)	19 (57.6%)	14 (70%)	0.1981 ^d

Data given in median (interquartile range) or in number of patients patients (percentage of group). p-values are calculated between groups using either ^cKruskal–Wallis test or ^dChi-Square test. BMI, body-mass-index; CPR, cardiopulmonary resuscitation; ECMO, extracorporeal membrane oxygenation; Vent., ventilation. Bold values indicate a p-value < 0.05.